News

Back

Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study

May 18th 2020

BioPark

First patients treated following resumption of clinical activities in Hong Kong
JTA-004 phase III study approved in five of seven territories

BONE THERAPEUTICS today announces it has commenced treating the first patients for the pivotal JTA-004 phase III clinical study in Hong Kong SAR. Several clinical trial sites in Europe are also expected to resume recruitment activities as COVID-19 lockdown measures are gradually being lifted.  Please discover the press release here.